

# NEXT SCIENCE®

## Launch of Online Sales of Next Science Acne Cream

**Sydney, Australia, Wednesday, 18 March 2020:** Next Science Limited (ASX:NXS) is pleased to announce the launch today of online sales of Next Science's Acne Cream via online skincare direct marketer, tbh Skincare, to consumers based in Australia, New Zealand, the UK and parts of Europe.

Acne is a common and often significantly debilitating skin condition, especially in adolescents and young adults. Commonly used over-the-counter treatments for acne include preparations containing salicylic acid, benzoyl peroxide or adapalene. In the prescription market, antibiotics (oral and topical) are used in the treatment of acne.

Next Science's Acne Cream treats acne using the Company's proprietary and patented Xbio™ technology in a non-salicylic acid based topical cream which is non-toxic and gentle on the skin. Next Science's Xbio™ technology physically breaks down the protective biofilm layer to expose acne bacteria and reduce acne symptoms.

Multi-site ongoing clinical testing of Next Science's Acne Cream shows superior results in the resolution of mild to moderate acne compared to leading competitive brands, including products containing benzoyl peroxide.

tbh Skincare has run its own trial of Next Science's Acne Cream with a sample group of 20 females. In conjunction with today's launch, tbh Skincare is sharing via its website and social media platforms, many of the success stories from this trial group.

This product launch is the first of the five new product launches announced previously for 2020.

Approved by the Board.

Further information:

**tbh Skincare website:** <https://tbhskincare.com/>

### **Judith Mitchell**

Managing Director, Next Science Limited  
Phone: +61 2 9375 7989  
Email: [investorqueries@nextscience.com](mailto:investorqueries@nextscience.com)

### **Michael Brown**

Pegasus Advisory  
Phone: +61 400 248 080  
Email: [mbrown@pegasusadvisory.com.au](mailto:mbrown@pegasusadvisory.com.au)

### **About Next Science**

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the Company's primary focus is on the development and commercialisation of its proprietary Xbio™ technology to reduce the impact of biofilm based infections in human health. Xbio is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its Xbio technology. Website: [www.nextscience.com](http://www.nextscience.com).